Benchmark reaffirmed their buy rating on shares of NeoGenomics (NASDAQ:NEO – Free Report) in a research note issued to investors on Wednesday morning, Benzinga reports. The firm currently has a $18.00 price objective on the medical research company’s stock. Other research analysts also recently issued reports about the company. William Blair restated an outperform rating […]